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1. Introduction {#s0005}
===============

Sublesional osteoporosis (SLOP) is a disease specific to the spinal cord injury (SCI) population associated with excess bone resorption paired with reduced bone formation below the level of lesion ([@bb0005]). The dramatic loss of bone mineral density (BMD) increases the risk of acquiring fragility fractures at the distal femur, proximal tibia, and hip regions ([@bb0005]). There is a preservation of BMD at the lumbar spine (LS) during the chronic phase of SCI, which may be due to the maintenance of load on the spine while sitting in a wheelchair ([@bb0010]). However the trabecular composition of the LS with high bone turnover can cause changes in BMD prior to fracture ([@bb0005]) and many vertebral compression fractures at this site go undetected in other clinical disorders such as steroid drug-induced bone loss ([@bb0015]). The occurrence of SLOP is estimated to be up to 82% in individuals with SCI ([@bb0005]). Although nutrition and adiposity have known roles in the regulation of bone metabolism, the importance of these factors compared to loss of weight bearing in those with SCI is not well defined.

Sub-optimal vitamin D status is common in the SCI population ([@bb0020], [@bb0035], [@bb0025], [@bb0030], [@bb0040]). It is attributed to limited exposure to sunlight due to reduced mobility, use of medications that accelerate vitamin D metabolism, and/or low vitamin D intake due to calcium-restricted diets during acute care to avoid hypercalciuria ([@bb0035]). Intake of calcium may thus also be compromised. Whether persons with greater fracture risk, such as the SCI population, require nutrient intakes higher than the dietary reference intakes suggested for the average population is unknown ([@bb0045], [@bb0050]).

Other factors that may influence bone formation and resorption in persons with SCI include pro-inflammatory cytokines released from excess adipose tissue ([@bb0055]). Leptin has been suggested to regulate bone metabolism primarily through the peripheral pathway promoting bone formation ([@bb0060], [@bb0065]). Leptin receptors on osteoblasts increase osteoblast differentiation while decreasing adipocyte differentiation, as they are both derived from a common multi-potential mesenchymal stem cell lineage ([@bb0070]). Excess adiposity also increases exogenous insulin, which binds to insulin receptors on osteoblast cells and directly induces osteoblast activity ([@bb0075]). Similarly, adiponectin may be a biomarker for bone loss and fracture risk as it is inversely related to BMD and central adiposity ([@bb0080]). Alternative theories regarding the fat--bone relationship suggest that mechanical loading by fat and muscle mass on bone tissue is associated with increased osteoblast activity, strengthening bones in regions of high stress ([@bb0085]). In persons with SCI, body weight percentage as adipose tissue mass can be 8--18% higher than in age-, height-, and/or weight-matched non-SCI controls ([@bb0090]). Following SCI, adipose tissue accumulation in parallel with loss of muscle and bone tissue indicates a disruption in adipose-associated bone metabolism ([@bb0085]).

The presence of SLOP ([@bb0005]), nutrient inadequacy ([@bb0095]), and obesity ([@bb0100]) in the SCI population suggests that a unique cross-regulation may exist. Characterizing relationships between markers of these physiologic states will further our understanding of bone health in the SCI population and may help in the detection and treatment of SLOP. This pilot study sought to assess bone-related measures of nutrition and obesity in a SCI cohort and determine if these measures are associated with BMD at the femoral neck (FN) and LS. Secondary goals were to identify correlates of suboptimal vitamin D status (e.g. winter assessment, vitamin D intake), and compare measurement outcomes to a small representative sample of non-SCI individuals.

2. Methods {#s0010}
==========

2.1. Study setting and population {#s0015}
---------------------------------

The study was conducted at McMaster University in Hamilton, Ontario, Canada; data were collected between March 2011 and April 2013. The Hamilton Integrated Health Sciences Research Ethics Board approved the study protocol and consent was obtained from each volunteer. Individuals enrolled in the study were at least 12 months post-SCI (traumatic or non-traumatic) ranging in impairment from C1 to T12, and ranging in severity from A to D as categorized by the American Spinal Injury Association Impairment Scale (AIS) ([@bb0105]). The non-SCI individuals serving as a comparison group were matched for sex, age, waist circumference (WC), and body mass index (BMI).

2.2. Outcome measures {#s0095}
---------------------

### 2.2.1. Medical history and demographics {#s0020}

Demographics, injury characteristics, and medical history were obtained by interview. Body mass was measured using a digital wheelchair scale (Detecto BRW-1000 Digital Bariatric Wheelchair Scale, DETECTO, Webb City, MO, USA) to the nearest 0.1 kg and body length was measured on the right side of the body while lying supine to the nearest 0.1 cm. WC was taken in the supine position after normal expiration immediately below the lowest rib with the same tape measure as used for participant length (Gulick II) ([@bb0110]). For each WC measurement, the tape measure was placed directly on the skin with the participants\' arms by their sides. Each measurement was taken to the nearest 0.1 cm.

### 2.2.2. Body composition {#s0025}

Dual energy X-ray absorptiometry (DXA) scans were performed using Hologic QDR-4500A (Hologic Inc., Waltham, MA, USA). Scan acquisition and analyses were completed following the manufacturers\' guidelines for assessing areal BMD (aBMD) at the LS (lumbar vertebrae 1--4 or a minimum of two consecutive vertebrae) and FN of the left hip ([@bb0100]); body fat and visceral adipose tissue (VAT) were analyzed from a whole body scan, where a demarcated region of interest from lumbar vertebrae 1 through 4 quantified VAT ([@bb0115]). Quality control tests were performed daily using a phantom, and measurements were maintained within the manufacturer\'s standards of \< 1%. Both T and Z-scores were calculated using a reference database for non-SCI individuals provided by the Hologic software; T-scores were used for participants over 50 years and Z-scores were used for participants under 50 years ([@bb0120]).

### 2.2.3. Food and supplemental nutrient intake {#s0030}

Average daily dietary intakes of calcium, vitamins D and K, and protein were assessed using a previously validated food frequency questionnaire (FFQ) ([@bb0125]). Supplement use of multivitamins, calcium, and vitamin D were documented regarding amount(s) and duration of use. Dietary nutrient intake refers to the consumption of the nutrient from food, whereas absolute nutrient intake refers to the consumption of food plus supplements. To assess the adequacy of nutrient intake, reported intakes were compared to the estimated average requirement (EAR) for vitamin D (400 IU/day), calcium (800 mg/day) and protein (0.66 g/kg/day) and the adequate intake of vitamin K (120 μg/day) for adults aged over 18 years as recommended by Health Canada ([@bb0135], [@bb0130], [@bb0140]).

### 2.2.4. Blood collection and analyses {#s0035}

Blood samples collected following a 12-hour fast were spun and frozen at − 80 °C. Plasma 25(OH)D was quantified in triplicate using ultra high performance liquid chromatography tandem mass spectrometry (UPLC/MS--MS). The protocol for sample preparation was based on the Waters Alliance and Hymoller and Jensen protocol for HPLC LC/MS--MS with minor modifications ([@bb0145], [@bb0150]). The coefficient of variation (CV) for low and high 25(OH)D quality control measurements run five times was \< 10%. Although there is no universal definition for optimal 25(OH)D status for bone health, the Institute of Medicine (IOM) defines adequacy as \> 50 nmol/L ([@bb0130]). We defined sub-optimal vitamin D status as \< 75 nmol/L as recommended by the International Symposium on the Nutrition Aspects of Osteoporosis for persons with increased risk of fracture ([@bb0155]). Serum samples were analyzed for leptin, insulin, and adiponectin using the Milliplex® Map Kit for Human Adipokine Magnetic Bead Panel 2 (Millipore Corporation, Billerica, CA) in duplicate.

2.3. Statistical analyses {#s0040}
-------------------------

Descriptive statistics were computed by calculating the mean (SD) and count (percent) for categorical variables. The primary objective was explored using multiple linear regression analyses to associate BMD (LS and FN) with calcium intake, 25(OH)D status, leptin, insulin, adiponectin, and VAT. To address the secondary objective of characterizing vitamin D status among those with SCI, the sample was dichotomized based on optimal (≥ 75 nmol/L) and suboptimal (\< 75 nmol/L) 25(OH)D. Univariate logistic regression analyses were then performed to identify whether the following characteristics were associated with suboptimal vitamin D status: winter assessment, inadequate absolute vitamin D intake (as defined by EAR), no vitamin D supplement use, no multivitamin supplement use, and medications affecting vitamin D metabolism. Seasonal variation of 25(OH)D was defined by samples collected in winter (November to April) or summer (May to October) months. Odd ratios (ORs), 95% confidence intervals (CI) and p-values were reported. Independent sample *t*-tests were performed between the whole SCI group (n = 34) and the SCI (n = 8) to ensure that our matched sample was representative of our cohort and between SCI (n = 8) and the matched non-SCI comparison group (n = 8), where p-value \< 0.05 was considered significant. Statistical analyses were performed using the Statistical Program for Social Sciences (SPSS) (version 19.0; SPSS Inc., Chicago, IL).

3. Results {#s0045}
==========

3.1. Recruitment and sample size {#s0050}
--------------------------------

A total of 34 SCI and 8 non-SCI participants were recruited to participate in the study, with a complete data set for 27 SCI and 8 non-SCI participants. Reasons for missing data included: metal interference with DXA, patient\'s weight exceeded the maximum capability of the DXA machine, loss of communication, and one participant declining blood draw.

3.2. Participant characteristics {#s0055}
--------------------------------

Participant and injury characteristics of the cohort consisting of 34 wheelchair-bound Caucasian participants with chronic SCI are summarized in [Table 1](#t0005){ref-type="table"}. Neurological lesions varied from C1 to T11 and severity category from A to D (A = 13, B = 4, C = 16, D = 1) by AIS. Sixty-two percent of the male participants with SCI were obese when considering their body fat percent (\> 25%), and 100% of the female SCI participants were obese (\> 32%) ([@bb0160]). The 8 male non-SCI participants who were sex, age, WC- and BMI-matched to 8 of the participants with paraplegia had a mean age of 42.5 (6.7) years, BMI of 25.8 (3.8) kg/m^2^, WC of 91.9 (9.48) cm and 20.70% body fat.

3.3. Outcome measures {#s0060}
---------------------

### 3.3.1. Bone mineral density and visceral adipose tissue {#s0065}

BMD and VAT outcomes are summarized in [Table 2](#t0010){ref-type="table"}. Based on the FN T and Z-scores, 32% of participants with SCI had lower than expected Z-scores for age and sex (≤ − 2), 11% were at an increased risk of fracture with low bone mass (T-score − 1 to − 2.5), 4% were at high risk of fracture and would be diagnosed with osteoporosis (T-score ≤ − 2.5) ([@bb0120]). SCI compared to non-SCI participants had a significantly lower FN BMD (p = 0.001) ([Table 2](#t0010){ref-type="table"}). All other measurement outcomes were not significantly different between SCI and non-SCI.

### 3.3.2. Dietary and supplemental nutrient intake {#s0070}

Intakes of vitamin D, calcium, vitamin K, and protein are summarized in [Table 2](#t0010){ref-type="table"}. Vitamin D supplements were consumed by 63% of the SCI cohort in amounts ranging from 500 to 2000 IU per day, with one individual reporting taking 50,000 IU weekly at the time of assessment; 50% of participants were consuming at least 1000 IU per day not including a multivitamin. SCI compared to non-SCI participants had a significantly higher vitamin D intake [Table 2](#t0010){ref-type="table"}. Calcium supplements of 300 to 2200 mg/day were consumed by 41% of participants with SCI and multivitamins containing between 400 and 800 IU of vitamin D and between 200 and 500 mg of calcium by 69% of participants. Without taking into account supplement intake (i.e. obtained from food only), 13% of the cohort fell below the EAR for calcium and 84% for vitamin D. Mean vitamin K and protein intakes were similar across SCI and non-SCI groups and exceeded the adequate intake of vitamin K (90--120 μg/day) and EAR of protein (0.66 g/kg/day) for females and males over 18 years ([Table 2](#t0010){ref-type="table"}).

### 3.3.3. Vitamin D status {#s0075}

Suboptimal plasma 25(OH)D status (\< 75 nmol/L) was observed in 60% of the SCI cohort, of which 10% were truly deficient (\< 30 nmol/L). Mean (SD) plasma 25(OH)D in the optimal category was 92.3 (12.0) nmol/L (n = 13) while in the suboptimal category was 54.4 (14.9) nmol/L (n = 20) for participants with SCI. Univariate logistic regression analyses revealed that participants with SCI not taking multivitamin supplements had increased odds of having suboptimal vitamin D status (OR = 0.171, CI = 0.033--0.893, p = 0.036). The mean 25(OH)D values for individuals with SCI consuming multivitamin supplements was 86.9 (21.2) nmol/L (n = 10) and for those without supplements was 63.1 (20.4) nmol/L (n = 23). No other potential correlates of deficient vitamin D status were significant in the SCI cohort. The vitamin D status of the SCI and non-SCI comparison groups was not significantly different, and 50% of the non-SCI group had suboptimal plasma 25(OH)D status ([Table 2](#t0010){ref-type="table"}).

### 3.3.4. Bone and adiposity measures {#s0080}

In participants with SCI, BMD at the FN and LS was significantly associated with leptin, insulin and VAT%, as was LS BMD with adiponectin ([Table 3](#t0015){ref-type="table"}). An example of the significant positive, moderate correlation found between FN BMD and VAT is presented in [Fig. 1](#f0005){ref-type="fig"}. None of the other outcome measures were significantly related to BMD at the FN or LS.

4. Discussion {#s0085}
=============

In our study cohort of 34 adults with chronic SCI, BMD at the FN and LS were associated with circulating adipokines and VAT, but not with any measure of nutrition. Sub-optimal bone status at the FN was significantly greater in participants with SCI than in a matched healthy reference group of non-SCI persons.

The positive associations found between BMD and VAT, leptin, insulin and adiponectin in the present study can be attributed to several potential mechanisms ([@bb0165]). It is postulated that higher body weight increases mechanical loading on bones, activating osteoblast cells for bone formation ([@bb0165]). Alternatively, metabolic factors may have an impact on BMD; greater adipose tissue is associated with higher secretion of bone-active hormones such as leptin and insulin, thereby directly stimulating osteoblast activity ([@bb0165]). Since the subpopulation of individuals with SCI experience a lack of mechanical loading below the level of lesion, metabolic influences from systemic hormone regulation are likely major contributors to BMD regulation.

Associations between adiposity measures and BMD were previously reported in a chronic SCI cohort ([@bb0170], [@bb0175]); our data support and extend the proposal that adipokines may be candidate biomarkers for BMD in SCI-related sublesional osteoporosis. A previous study reported an inverse relationship between circulating adiponectin and SLOP in SCI wheelchair users rather than walkers, but the site of BMD measure was not indicated ([@bb0170]). These findings suggest that osteoprotective benefits of obesity require mechanical loading in order to mitigate the resorptive effects of adiponectin ([@bb0075]). Another study compared individuals with SCI to their non-SCI monozygotic twin, and reported significant positive relationships between leg BMD or BMC with total body fat percent, leg fat mass and serum estradiol in the SCI group, where only leg lean mass was correlated to leg BMD or BMC among the non-SCI twins ([@bb0175]). The markers of adiposity in relation to lower extremity BMD are consistent with our findings. This relationship may be site-specific due to the redistribution of fat and muscle mass following SCI, where leg fat mass was the most significant predictor of leg BMD/BMC ([@bb0175]). The positive association between adiponectin and BMD at the LS, but not the FN site found in our study, could be specific to the site of bone preservation due to the constant weight bearing in a seated position. LS preservation is evident in the comparable LS BMD of non-SCI controls. Alternatively, DXA has been found to overestimate the LS BMD in SCI due to confounding osteophytes or heterotrophic ossification ([@bb0180]), and may mask bone loss following injury.

Following SCI, the gain in adipose tissue concurrent with the loss of lean and bone tissue results in a redistribution of body composition and a decreased metabolic rate ([@bb0185]). Since people with SCI have higher adipose mass, lower circulating adiponectin compared to non-SCI controls would be expected. Our results found slightly higher circulating adiponectin in SCI than non-SCI as seen in previous studies ([@bb0110], [@bb0190]), indicating that the hormonal mechanism of adiponectin on fat and bone metabolism may differ in persons with SCI. Alternatively, low resting metabolism after SCI may protect against hypoadiponectinemia ([@bb0195]). A further explanation for the unexpected adiponectin findings is that persons with SCI produce biologically inactive forms of adiponectin ([@bb0200], [@bb0205]). The analysis methodology used for assessing circulating adiponectin measures various forms including both biologically active and inactive adiponectin, possibly impacting the results ([@bb0190]).

Although nutritional status was not associated with bone outcomes in the SCI cohort, it is worth noting that to achieve recommended intake of nutrients, the participants with SCI were highly reliant on supplements; 73% of the participants reported calcium, vitamin D and/or multivitamin supplementation. Vitamin D was the main nutrient with suboptimal intakes when accounted from food sources only. Frequent use of nutrient supplementation has been observed previously in a cohort of 77 adults with SCI, where 50% of participants consistently took multivitamin, calcium and vitamin D supplements ([@bb0210]). Quite remarkably, despite the observed frequency of vitamin D supplementation, 60% of the participants with SCI demonstrated suboptimal 25(OH)D status. These findings align with previous reports where 32% of persons with SCI (n = 100) had suboptimal 25(OH)D status (defined as \< 40 nmol/L) ([@bb0035]). However, when the cut-off of 70--80 nmol/L is employed, more recent reports of suboptimal 25(OH)D status were as high as 93% in SCI cohorts ([@bb0215]). Multivitamin use was the only correlate associated with vitamin D inadequacy, most likely due to the high amounts of calcium and vitamin D present and other nutrients improving their absorption. Taken together, data from the present study and other reports indicate that greater intakes of vitamin D with more reliance on supplementation as well as clinical monitoring may be necessary for reaching adequate 25(OH)D status in SCI populations.

The lack of a relationship between BMD and skeletal nutrient intake or 25(OH)D status may be attributable to the wide variability of injury characteristics in our cohort, or other factors known to influence low BMD including: injury duration greater than 10 years, motor complete injury, female gender, BMI less than 19, medications that increase vitamin D metabolism and excessive cigarette smoking or alcohol intake ([@bb0020]). The lack of impact of nutrient intake on bone status was observed in a study examining the factors contributing to steroid-induced osteoporosis in children with rheumatic disorders or nephrosis, possibly due to the overwhelming impact of glucocorticoid use ([@bb0220], [@bb0225], [@bb0230]). Significant associations between 25(OH)D status and BMD at the hip have been observed in non-SCI women over the age of 60 ([@bb0155]), but this relationship has not been previously reported in SCI. In our SCI cohort, bone loss appeared site specific at the FN, whereas bone mass was preserved in the LS. Future research should include evaluations of BMD at the proximal tibia and distal femur sites, where the highest incidence of fractures occurs ([@bb0005]). The observation of significantly lower FN BMD in our participants with SCI in comparison to non-SCI was expected since aBMD is known to decline by 20--32% within the first year of injury, particularly in the lower extremities ([@bb0005]).

Limitations to the current study include the cross-sectional observational design, which does not allow for observations to be made with regards to the chronology of outcomes or causality of relationships between different outcomes. Many of our participants were recruited from the MacWheelers Rehabilitation Centre at McMaster University and may not be generalizable to all persons with SCI due to their habitual exercise routine. In addition, the small and heterogeneous sample size did not allow confounding covariates of inadequate 25(OH)D status and sub-optimal bone status to be controlled.

5. Conclusions {#s0090}
==============

The results of this study found that markers of adiposity were closely related to BMD at the FN and LS skeletal sites in adults with chronic SCI, while nutrition and 25(OH)D status showed no association with BMD. The observed positive correlations between adiposity markers with BMD suggest that higher hormone levels resulting from greater adipose tissue, rather than mechanical weight bearing, may activate bone remodeling in the SCI population. Further understanding of the relationships between adiposity and bone health may help to identify the effects of the drastic body composition changes during the acute and chronic phases of SCI. With increasing rates of SCI predicted in the coming decades ([@bb0235]), research on accurate prevention, treatment, and rehabilitation of SLOP is necessary to improve the quality of life of individuals with SCI and reduce healthcare costs.
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![Relationship between bone mineral density (BMD) at the femoral neck (g/cm^2^) and visceral adipose tissue (VAT) (%) (r^2^ = 0.444; p-value = 0.018).](gr1){#f0005}

###### 

Participant and injury characteristics of SCI cohort. Values are mean (SD).\* n = 29

  Subject characteristics (n = 34)   
  ---------------------------------- -----------------
  Male/female (n)                    32/2
  Age (years)                        40.0 (10.9)
  Height (m)                         1.75 (0.08)
  Mass (kg)                          82.1 (16.6)
  BMI (kg/m^2^)                      26.5 (4.7)
  WC (cm)                            93.0 (13.6)
  Body fat (%)\*                     28.4 (7.3)
                                     
  Injury characteristics             \# Participants
                                     
  Motor complete/Incomplete (n)      17/17
  Tetraplegia/Paraplegia (n)         22/12
  Traumatic/Non-traumatic (n)        27/7
  Time post injury (years)           12.7 (9.9)

###### 

Outcome measures for participants with spinal cord injury (SCI) for whole group and for SCI compared to matched non-SCI comparison group.

                                 SCI               SCI vs non-SCI   p-Value                       
  ------------------------------ ----------------- ---------------- --------------- ------------- -------
  *Bone mineral density*                                                                          
  Femoral neck BMD (g/cm^2^)     N                 28               7               8             
  Mean (SD)                      0.69 (0.19)       0.63 (0.16)      0.92 (0.12)     0.001         
  T-score                        − 1.04 (n = 5)    − 2.50 (n = 1)   − 0.9 (n = 2)   N/A           
  Z-score                        − 1.49 (n = 23)   − 1.70 (n = 6)   0.68 (n = 6)    N/A           
  Lumbar spine BMD (g/cm^2^)     N                 27               8               8             
  Mean (SD)                      1.12 (0.17)       1.12 (0.2)       1.08 (0.10)     0.630         
  T-score                        0.37 (n = 6)      0.15 (n = 2)     − 0.4 (n = 2)   N/A           
  Z-score                        0.29 (n = 21)     0.25 (n = 6)     0.07 (n = 6)    0.837         
  Visceral adipose tissue (kg)   N                 29               8               8             
  Mean (SD)                      3.11 (1.47)       2.75 (1.42)      2.29 (1.44)     0.533         
  VAT (%)                        29.1 (8.73)       26.7 (8.69)      22.0 (8.8)      0.298         
                                                                                                  
  **Total nutrient intake**      N                 32               8               8             
  Vitamin D (IU/day)             Mean (SD)         1224 (1315)      1321 (696)      396 (288)     0.007
  Range                          155--7413         250--2246        4--907                        
  \% below EAR                   31.3              25.0             62.5            0.149         
  Calcium (mg/day)               Mean (SD)         1611 (787)       1765 (679)      1613 (907)    0.712
  Range                          63--3646          1014--2440       236--3117                     
  \% below EAR                   9.4               0                25.0            0.149         
  Vitamin K (μg/day)             Mean (SD)         193 (212)        172 (175)       254 (289)     0.505
  Range                          15--1181          17--528          66--934                       
  Protein (g/day)                Mean (SD)         82 (36)          90 (29)         93 (39)       0.859
  Range                          23--186           51--139          12--144                       
  \% below EAR                   25.0              12.5             12.5            1.000         
                                                                                                  
  **Blood biomarkers**           N                 33               8               8             
  25 (OH)D (nmol/L)              Mean (SD)         69.3 (23.3)      89.9 (14.3)     76.5 (19.8)   0.144
  Range                          18--120           69--104          50--115                       
  Leptin (ng/mL)                 Mean (SD)         14.8 (31.4)      5.1 (3.3)       5.7 (5.2)     0.770
  Range                          0.21--180         0.21--10.6       1--16                         
  Insulin (pg/L)                 Mean (SD)         288 (234)        204 (89)        236 (116)     0.543
  Range                          58--1180          90--320          111--437                      
  Adiponectin (ng/mL)            Mean (SD)         40.5 (44.0)      24.9 (23.3)     18.7 (10.5)   0.505
  Range                          8-200             11--81           7.2--39.9                     

Values are mean (SD). BMD T-score was calculated in participants \> 50 years; Z-score was calculated in participants \< 50 years. p-Value represents independent *t*-test between matched SCI and non-SCI groups.

###### 

Multiple linear regression analyses for measurements in participants with SCI (n = 25-27).

  Variables        Unstandardized coefficients   r       P-value   95.0% CI                                 
  ---------------- ----------------------------- ------- --------- ---------------------------------------- ------------
  *BMD FN*                                                                                                  
  Calcium intake   0.000                         0.000   0.115     0.561                                    0.00--0.00
  25(OH)D          − 0.002                       0.002   − .221    0.268                                    0.00--0.00
  Leptin           0.010                         0.003   .529      0.005[⁎](#tf0005){ref-type="table-fn"}   0.00--0.02
  Insulin          0.000                         0.000   .544      0.003[⁎](#tf0005){ref-type="table-fn"}   0.00--0.00
  Adiponectin      0.000                         0.001   .227      0.255                                    0.00--0.00
  VAT %            0.010                         0.004   .444      0.018[⁎](#tf0005){ref-type="table-fn"}   0.00--0.02
                                                                                                            
  *BMD LS*                                                                                                  
  Calcium intake   0.000                         0.000   .026      0.899                                    0.00--0.00
  25(OH)D          0.000                         0.001   .009      0.996                                    0.00--0.00
  Leptin           0.007                         0.003   .392      0.048[⁎](#tf0005){ref-type="table-fn"}   0.00--0.01
  Insulin          0.000                         0.000   .388      0.050[⁎](#tf0005){ref-type="table-fn"}   0.00--0.00
  Adiponectin      0.002                         0.001   .429      0.029[⁎](#tf0005){ref-type="table-fn"}   0.00--0.00
  VAT %            0.008                         0.004   .381      0.048[⁎](#tf0005){ref-type="table-fn"}   0.00--0.02

P-value \< 0.05.
